Abstract: An immunotherapeutic protein and methods of use and production thereof are disclosed, wherein the immunotherapeutic protein comprises, for example, a cell surface receptor polypeptide which is a cellular entry receptor for the entry of a virus into a host cell, which is linked to a polypeptide comprising an Fc region component. When the cell surface receptor polypeptide is an angiotensin converting enzyme 2 (ACE2) polypeptide or a fragment thereof, the immunotherapeutic protein is capable of binding to a coronavirus spike protein (S protein) and may be useful as an antiviral agent for the prevention or treatment of a coronavirus infection. The Fc region component may comprise an amino acid substitution at the position corresponding to H429 of the amino acid sequence of the human IgG1 heavy chain polypeptide which may enable the production of soluble oligomeric forms or the assembly of oligomeric forms from soluble monomeric forms upon binding to an S protein of a coronavirus (i.e.

Abstract: The invention relates to the field of medical diagnostics. In particular, it relates to compositions, methods and kits for detecting immune cells for diagnosis of allergy, for monitoring of vaccination responses, for determining immune response to pathogens and of treatment efficacy of allergen immunotherapy. For example, the invention provides a method of determining allergic reactivity in a subject, the method comprising, providing a sample from a subject, contacting the sample with a recombinant or synthetic allergen linked to a detectable label in conditions for permitting the binding of the allergen to an IgE molecule present in the sample, determining the binding of the allergen to an IgE molecule in the sample by detecting the label, wherein the detection of the label indicates the subject has allergic reactivity.

Abstract: Immunotherapeutic proteins comprising at least one heavy chain polypeptide derived from an IgG2 antibody are disclosed, wherein the heavy chain polypeptide comprises at least constant heavy domains 2 and 3 (CH2 and CH3) and the lower hinge, and the sequence of the lower hinge comprises a mutation enabling the immunotherapeutic protein to bind to and/or activate Fc?RIIb. The immunotherapeutic protein is suitable for use in methods of treating diseases or conditions wherein, for example, the activation of Fc?RIIb (ie for recruitment of the inhibitory functions of Fc?RIIb) is beneficial, such as allergic diseases.

Abstract: The present disclosure relates to the use of an at least one soluble Fc binding multimer comprising at least two Fc binding regions to assess FcR binding activity of an at least one polypeptide comprising an Fc region or fragment thereof, including an antibody, and methods and assays of using the Fc binding multimer to assess FcR binding activity. The FcR binding multimer may be a fusion polypeptide comprising an at least two Fc binding regions, or may consist of at least two peptides each comprising at least one Fc binding region, that are covalently or non-covalently oligomerised.

Abstract: A soluble multimeric protein or polypeptide is disclosed that is able to inhibit interaction of leukocyte Fc? receptors (Fc?R) and immunoglobulin G (IgG). The protein or polypeptide comprises two or more linked Fc binding regions, at least one of which is derived from an Fc?R type receptor and, particularly, Fc?RIIa. Also described are polynucleotide molecules encoding the protein or polypeptide and the use thereof in methods of treating a subject for an immune-complex (IC)-mediated inflammatory disease.

Abstract: A soluble multimeric protein or polypeptide is disclosed that is able to inhibit interaction of leukocyte Fc? receptors (Fc?R) and immunoglobulin G (IgG). The protein or polypeptide comprises two or more linked Fc binding regions, at least one of which is derived from an Fc?R type receptor and, particularly, Fc?RIIa. Also described are polynucleotide molecules encoding the protein or polypeptide and the use thereof in methods of treating a subject for an immune-complex (IC)-mediated inflammatory disease.

Abstract: This invention relates to a method of inhibiting Fc receptor binding of immunoglobulin including the use of a Fc receptor modulating compound which binds to defined surfaces on a Fc receptor. The present invention also relates to a method for treating a variety of diseases using a Fc receptor modulating compound.

Abstract: The present invention provides a Fc?RIIa transgenic non-human animal model for autoimmune disease, particularly arthritis. This invention also provides a method of using this model to screen compounds that can reduce aberrant immune activity including aberrant immune complex formation aberrant immune complex clearance and immune complex induced inflammation. This invention also provides means of using this model to treat or prevent autoimmune disease.

Abstract: Methods for inhibiting Fc receptor binding of immunoglobulin in a patient comprising administering pharmaceutical compositions comprising Fc modulating compounds are disclosed.

Abstract: The present invention generally relates to molecules having Fc binding ability such as those with Fc receptor-like activity. The present invention also relates to the molecules, nucleic acids encoding the molecules, antagonist compounds, pharmaceutical compositions comprising the molecules and compounds, methods for testing potential antagonists, methods for producing the polypeptides, methods of treatment of disease and other aspects.

Abstract: Disclosed are crystals, crystal structure Fc&ggr;RIIa protein, three dimensional coordinates of Fc&ggr;RIIa protein, and structures and models derived from the Fc&ggr;RIIa structure. Also disclosed are crystals of Fc&egr;RI protein and three dimensional coordinates of Fc&egr;RI protein monomers and dimers derived from the Fc&ggr;RIIa structure. Also disclosed are three dimensional coordinates of Fc&ggr;RIIIb proteins and models of Fc&ggr;RIIIb derived from the Fc&ggr;RIIa structure. The present invention also includes methods to produce such crystals, crystal structures and models. Uses of such crystals, crystal structures and models are also disclosed, including structure based drug design and therapeutic compositions.

Abstract: Disclosed are crystals, crystal structure Fc&ggr;RIIa protein, three dimensional coordinates of Fc&ggr;RIIa protein, and structures and models derived from the Fc&ggr;RIIa structure. Also disclosed are crystals of Fc&egr;RI protein and three dimensional coordinates of Fc&egr;RI protein monomers and dimers derived from the Fc&ggr;RIIa structure. Also disclosed are three dimensional coordinates of Fc&ggr;RIIIb proteins and models of Fc&ggr;RIIIb derived from the Fc&ggr;RIIa structure. The present invention also includes methods to produce such crystals, crystal structures and models. Uses of such crystals, crystal structures and models are also disclosed, including structure based drug design and therapeutic compositions.

Abstract: Disclosed are crystals, crystal structure Fc&ggr;RIIa protein, three dimensional coordinates of Fc&ggr;RIIa protein, and structures and models derived from the Fc&ggr;RIIa structure. Also disclosed are crystals of Fc&egr;RI protein and three dimensional coordinates of Fc&egr;RI protein monomers and dimers derived from the Fc&ggr;RIIa structure. Also disclosed are three dimensional coordinates of Fc&ggr;RIIIb proteins and models of Fc&ggr;RIIIb derived from the Fc&ggr;RIIa structure. The present invention also includes methods to produce such crystals, crystal structures and models. Uses of such crystals, crystal structures and models are also disclosed, including structure based drug design and therapeutic compositions.

Abstract: This invention relates to a pharmaceutical composition comprising a Fc receptor modulating compound and a pharmaceutically acceptable carrier. The present invention also relates to a method for treating a variety of diseases using a Fc receptor modulating compound.

Abstract: This invention relates to a pharmaceutical composition comprising a Fc receptor modulating compound and a pharmaceutically acceptable carrier. The present invention also relates to a method for treating a variety of diseases using a Fc receptor modulating compound.